The inactivation of the Niemann Pick C1 cholesterol transporter restricts SARS-CoV-2 entry into host cells by decreasing ACE2 abundance at the plasma membrane.

The inactivation of the Niemann Pick C1 cholesterol transporter restricts SARS-CoV-2 entry into host cells by decreasing ACE2 abundance at the plasma membrane.

Publication date: Dec 20, 2024

The Niemann Pick C1 (NPC1) protein is an intracellular cholesterol transporter located in the late endosome/lysosome (LE/Ly) that is involved in the mobilization of endocytosed cholesterol. Loss-of-function mutations in the NPC1 gene lead to the accumulation of cholesterol and sphingolipids in LE/Ly, resulting in severe fatal NPC1 disease. Cellular alterations associated with NPC1 inactivation affect both the integrity of lipid rafts and the endocytic pathway. Because the angiotensin-converting enzyme 2 (ACE2) and type 2 serine transmembrane protease (TMPRSS2), interactors of the SARS-CoV-2 Spike protein also localize to lipid rafts, we sought to investigate the hypothesis that NPC1 inactivation would generate an intrinsically unfavorable barrier to SARS-CoV-2 entry. In this study, we show that inhibition of the cholesterol transporter activity of NPC1 in cells that express both ACE2 and TMPRSS2, considerably reduces SARS-CoV-2 infectivity, evaluated as early as 4 h post-infection. Mechanistically, treatment with NPC1 specific inhibitor U18666A relocalizes ACE2 from the plasma membrane to the autophagosomal/lysosomal compartment, thereby reducing SARS-CoV-2 entry into treated cells. Reduction of viral entry was observed for both fully infectious SARS-CoV-2 virus and with a pseudotyped VSV-Spike-GFP virus. For instance, U18666A-treated Caco-2 cells infected with the pseudotyped VSV-Spike-GFP showed a > threefold and > 40-fold reduction in virus titer when infectivity was measured at 4 h or 24 h post-infection, respectively. A similar effect was observed in CRISP/R-Cas9-edited Caco-2 cells, which were even more resistant to SARS-CoV-2 infection as indicated by a 97% reduction of viral titers. Overall, this study provides compelling evidence that the inhibition of NPC1 cholesterol transporter activity generates a cellular environment that hinders SARS-CoV-2 entry. ACE2 depletion from the plasma membrane appears to play a major role as limiting factor for viral entry.

Open Access PDF

Concepts Keywords
Autophagosomal ACE2
Cholesterol Lipid dyshomeostasis
Host Spike-ACE2 interaction
Niemann Virus entry
Rafts

Semantics

Type Source Name
drug DRUGBANK Cholesterol
disease IDO entry into host
disease IDO protein
pathway KEGG Lysosome
drug DRUGBANK Serine
disease IDO infectivity
disease MESH infection
disease MESH virus titer
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease IDO role
pathway REACTOME Reproduction
disease MESH virus infection
disease IDO host
pathway KEGG Endocytosis
pathway KEGG Cholesterol metabolism
drug DRUGBANK Streptomycin
drug DRUGBANK Methylergometrine
disease MESH MCD
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Phosphate ion
drug DRUGBANK Gold
drug DRUGBANK Tromethamine
drug DRUGBANK Edetic Acid
disease IDO replication
drug DRUGBANK Sucrose
disease IDO assay
drug DRUGBANK Carboxymethylcellulose
drug DRUGBANK Formaldehyde
drug DRUGBANK Water
drug DRUGBANK Gentian violet cation
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Proline
disease IDO primary infection
disease MESH re infection
disease MESH death
drug DRUGBANK Hyaluronic acid
drug DRUGBANK Albendazole
pathway KEGG Viral replication
disease IDO process

Original Article

(Visited 1 times, 1 visits today)